Cellectar Biosciences Announces Two Peer Reviewed Studies Demonstrating the Capabilities of the PDC Platform
January 31, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces the advance...
Cellectar Biosciences to Present at NobleCon13
January 26, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announced today that its president and CEO, Jim...
Cellectar Biosciences Announces Additional US Patent Granted for CLR 131 and CLR 125 in a Broad Range of Solid Tumors
January 24, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Jan. 24, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces that the United States Patent...
Cellectar Biosciences to Present at the 9th Annual Biotech Showcase
January 05, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announces today that President and CEO, Jim...
Cellectar Biosciences Announces US and Japanese Patent Allowances for Diagnostic and Optical Imaging PDCs
December 20, 2016 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Dec. 20, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused clinical stage biotechnology company, today announces two patent...
Cellectar Biosciences Announces USPTO Grants Patent Allowances for Radiotherapeutic PDCs for A Variety of Solid Tumor Types
December 14, 2016 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused clinical stage biotechnology company, today announced that the...
Cellectar Biosciences Announces USPTO Grants Patent for Paclitaxel PDC; Provides Additional Patent Protection for Select Solid Tumors Through 2035
December 12, 2016 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused clinical stage biotechnology company, today announced that the...
Cellectar Biosciences Presents Poster at the 58th Annual Meeting of the American Society of Hematology
December 06, 2016 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announced that it...
Cellectar Biosciences Announces Results From the First Two Cohorts of Its CLR 131 Phase 1 Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, and Progression Free Survival Similar to or Better than Recently Approved Therapies
December 01, 2016 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today provides a data update...
Cellectar Biosciences Announces Successful Completion of $9.2 Million Public Offering, Which Includes Full Exercise of $1.2 Million Over-Allotment Option
November 29, 2016 18:40 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("Cellectar" or the "company"), an oncology-focused, clinical stage biotechnology company, today...